Cargando…

Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti‐interleukin‐5 receptor antibody

Benralizumab is an interleukin‐5 (IL‐5) receptor α‐directed cytolytic monoclonal antibody that reduces rapid and nearly complete depletion of eosinophils by enhancing antibody‐dependent cell‐mediated cytotoxicity. The depletion of eosinophilic inflammation is expected to reduce mucus hypersecretion...

Descripción completa

Detalles Bibliográficos
Autores principales: Takimoto, Takayuki, Kagawa, Tomoko, Tachibana, Kazunobu, Arai, Toru, Inoue, Yoshikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300730/
https://www.ncbi.nlm.nih.gov/pubmed/32566229
http://dx.doi.org/10.1002/rcr2.599